The ACTIV-6 trial investigated the effectiveness of inhaled fluticasone furoate on mild-to-moderate COVID-19 cases and found it did not accelerate recovery or prevent clinical progression compared to a placebo. Interestingly, vaccinated participants showed slightly faster recovery when treated with the drug, while unvaccinated participants did not.
BioNTech’s ‘extensive’ cancer pipeline comes into focus, with emphasis on ADCs
BioNTech, one of the biotech startups that helped vaccinate billions of people around the world against Covid-19, is starting to look like a cancer company.
November 9, 2023